SGLT2 inhibition with dapagliflozin: A novel approach for the management of type 2 diabetes

Gary Kilov, Stephen Leow, Merlin Thomas

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)


Background: Because of the progressive nature of the disease, most patients with type 2 diabetes mellitus eventually require multiple treatments to achieve glycaemic targets. The majority of available therapies are insulin dependent, aiming to decrease insulin resistance and increase insulin secretion. Sodium glucose co-transporter 2 (SGLT2) inhibitors, a new class of antidiabetic agents, limit renal glucose reabsorption promoting urinary excretion of glucose, thereby reducing plasma glucose. Objective: This article explores the mechanism of action and clinical data surrounding SGLT2 inhibitors, with a particular focus on dapagliflozin. Conclusion: Clinical trials have shown dapagliflozin to be effective in reducing glycosylated haemoglobin, weight and fasting plasma glucose, either as monotherapy or as add-on therapy to metformin, sulphonylurea and insulin. Other SGLT2 inhibitors are currently under investigation.

Original languageEnglish
Pages (from-to)706-710
Number of pages5
JournalAustralian Family Physician
Issue number10
Publication statusPublished - 25 Oct 2013
Externally publishedYes


  • Dapagliflozin
  • Diabetes mellitus
  • Hypoglycaemic agents
  • Sodium-glucose transport proteins/antagonists and inhibitors
  • Type 2

Cite this